19 / 28
Patient-Reported Outcomes With Durvalumab After
Chemoradiation in Locally Advanced, Unresectable
NSCLC: Data From PACIFIC
Rina Hui
1
, Mustafa Özgüroğlu
2
, Davey Daniel
3
, David Vicente Baz
4
, Shuji Murakami
5
, Takashi Yokoi
6
, Alberto Chiappori
7
, Ki Hyeong Lee
8
, Maike de
Wit
9
, Byoung Chul Cho
10
, Jhanelle E. Gray
7
, Anna Rydén
11
, Louis Viviers
12
, Lynne Poole
13
, Phillip A. Dennis
14
, Scott J. Antonia
7
1
Westmead Hospital and the University of Sydney, Sydney, NSW, Australia;
2
Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey;
3
Sarah Cannon Research Institute,
Nashville and Tennessee Oncology, Chattanooga, TN, USA;
4
Hospital Universitario Virgen Macarena, Seville, Spain;
5
Kanagawa Cancer Center, Yokohama, Japan;
6
Kansai Medical
University Hospital, Hirakata, Japan;
7
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA;
8
Chungbuk National University Hospital, Cheongju-si, Korea;
9
Vivantes
Klinikum Neukoelln, Berlin, Germany;
10
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea;
11
AstraZeneca, Gothenburg, Sweden;
12
QuintilesIMS, Saint Ouen
Cedex, France;
13
Astrazeneca, Cambridge, UK;
14
AstraZeneca, Gaithersburg, MD, USA
Presented by: Dr Rina Hui